Glück Conviction Score™ ⓘ
NKTR
NEKTAR THERAPEUTICS
Effektiv: Schwach
Mittel
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
74,1
66 neu, 76 erhöht, 1178,3M $ netto
Aktivist
56,7
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bärisch | 10 % | 75.19 | -21.0 % vs SMA50 | |
| Kurs vs SMA200 | Bärisch | 15 % | 60.11 | -1.2 % vs SMA200 | |
| EMA20 vs EMA50 | Bärisch | 5 % | 63.50 | EMA50: 68.99 | |
| MACD-Histogramm | Bullisch | 10 % | 0.079 | Bullisch | |
| RSI(14) | Neutral | 10 % | 32.7 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 39.2 | Neutral | |
| ADX(14)+DI | Bärisch | 10 % | 42.7 | +DI: 12.2 / −DI: 30.3 | |
| Z-Score(60) | Neutral | 5 % | -1.42 | In Range | |
| 52W-Position | Neutral | 5 % | 55.4 % | Hoch 100.35 / Tief 8.51 | |
| Bollinger(20,2σ) | Neutral | 5 % | 31.2 % | Upper 72.40 / Mid 62.93 / Lower 53.47 | |
| LinReg-Slope(60) | Neutral | 10 % | -0.3168 | R²=0.26 / annualisiert -106.9 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -444 | 65,51 | -29.086,44 | -59,0% | |
| 2026-05-19 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -199 | 65,51 | -13.036,49 | -26,5% | |
| 2026-02-18 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -180 | 73,00 | -13.140,00 | -26,7% | |
| 2026-02-18 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -423 | 73,00 | -30.879,00 | -62,7% | |
| 2026-01-20 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -3.867 | 35,67 | -137.935,89 | -279,9% | |
| 2025-11-25 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -1.157 | 54,28 | -62.801,96 | -127,5% | |
| 2025-11-25 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -2.207 | 54,28 | -119.795,96 | -243,1% | |
| 2025-11-25 | Wilson Mark Andrew | Officer, Chief Legal Officer | Open Market Sale | -630 | 54,28 | -34.196,40 | -69,4% | |
| 2025-09-09 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1.200 | 46,41 | -55.692,00 | -113,0% | |
| 2025-09-09 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -2.156 | 47,49 | -102.388,44 | -207,8% | |
| 2025-09-09 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -2.100 | 45,16 | -94.836,00 | -192,5% | |
| 2025-09-09 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1.210 | 48,18 | -58.297,80 | -118,3% | |
| 2025-09-05 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1.136 | 39,89 | -45.315,04 | -92,0% | |
| 2025-09-05 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -2.226 | 38,82 | -86.413,32 | -175,4% | |
| 2025-09-05 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -3.304 | 37,87 | -125.122,48 | -253,9% | |
| 2025-09-04 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -432 | 33,60 | -14.515,20 | -29,5% | |
| 2025-09-04 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -613 | 34,40 | -21.087,20 | -42,8% | |
| 2025-09-04 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1.134 | 35,80 | -40.597,20 | -82,4% | |
| 2025-09-04 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1.496 | 33,54 | -50.175,84 | -101,8% | |
| 2025-09-04 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1.923 | 32,37 | -62.247,51 | -126,3% | |
| 2025-09-04 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -189 | 34,41 | -6.503,49 | -13,2% | |
| 2025-09-04 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -307 | 35,69 | -10.956,83 | -22,2% | |
| 2025-09-04 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -793 | 32,43 | -25.716,99 | -52,2% | |
| 2025-09-02 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -485 | 30,10 | -14.598,50 | -29,6% | |
| 2025-09-02 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1.500 | 30,16 | -45.240,00 | -91,8% | |
| 2025-08-19 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1.573 | 26,59 | -41.826,07 | -84,9% | |
| 2025-08-19 | Wilson Mark Andrew | Officer, Chief Legal Officer | Open Market Sale | -676 | 26,59 | -17.974,84 | -36,5% | |
| 2025-08-19 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -725 | 26,59 | -19.277,75 | -39,1% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| FMR LLC | 4.303.188 | 101.129 | 4.202.059 | 309.614.403 | Aufgestockt | +4155,1% | |
| BVF INC/IL | 2.559.595 | 1.559.595 | 1.000.000 | 184.162.860 | Aufgestockt | +64,1% | |
| Two Seas Capital LP | 1.959.178 | 745.185 | 1.213.993 | 140.962.857 | Aufgestockt | +162,9% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.197.055 | 0 | 1.197.055 | 86.128.107 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 930.741 | 473.014 | 457.727 | 66.966.815 | Aufgestockt | +96,8% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 903.190 | 1.158.310 | -255.120 | 64.984.521 | Reduziert | -22,0% | |
| Prosight Management, LP | 735.000 | 554.633 | 180.367 | 52.883.250 | Aufgestockt | +32,5% | |
| BlackRock, Inc. | 692.650 | 645.607 | 47.043 | 49.836.168 | Aufgestockt | +7,3% | |
| CITADEL ADVISORS LLC | 665.431 | 489.377 | 176.054 | 47.877.760 | Aufgestockt | +36,0% | |
| MORGAN STANLEY | 659.387 | 566.421 | 92.966 | 47.442.895 | Aufgestockt | +16,4% | |
| VANGUARD GROUP INC | 1.027.089 | 0 | 1.027.089 | 43.425.322 | Neu | +100,0% | |
| ARMISTICE CAPITAL, LLC | 578.000 | 596.000 | -18.000 | 41.587.100 | Reduziert | -3,0% | |
| Invesco Ltd. | 567.458 | 468.159 | 99.299 | 40.828.603 | Aufgestockt | +21,2% | |
| Sofinnova Investments, Inc. | 509.546 | 438.630 | 70.916 | 36.661.835 | Aufgestockt | +16,2% | |
| Woodline Partners LP | 415.335 | 104.000 | 311.335 | 29.883.353 | Aufgestockt | +299,4% | |
| MILLENNIUM MANAGEMENT LLC | 404.277 | 454.075 | -49.798 | 29.087.730 | Reduziert | -11,0% | |
| Bronte Capital Management Pty Ltd. | 400.756 | 0 | 400.756 | 28.834.394 | Neu | +100,0% | |
| EMERALD ADVISERS, LLC | 394.604 | 384.342 | 10.262 | 28.391.758 | Aufgestockt | +2,7% | |
| Qube Research & Technologies Ltd | 390.675 | 323.915 | 66.760 | 28.109.066 | Aufgestockt | +20,6% | |
| GEODE CAPITAL MANAGEMENT, LLC | 346.795 | 254.361 | 92.434 | 24.961.900 | Aufgestockt | +36,3% | |
| UBS Group AG | 320.172 | 287.561 | 32.611 | 23.036.375 | Aufgestockt | +11,3% | |
| GREAT POINT PARTNERS LLC | 316.453 | 210.732 | 105.721 | 22.768.793 | Aufgestockt | +50,2% | |
| Vestal Point Capital, LP | 285.000 | 0 | 285.000 | 20.505.750 | Neu | +100,0% | |
| 22NW, LP | 281.115 | 331.115 | -50.000 | 20.226.224 | Reduziert | -15,1% | |
| PRIMECAP MANAGEMENT CO/CA/ | 279.150 | 280.150 | -1.000 | 20.084.842 | Reduziert | -0,4% | |
| ORBIMED ADVISORS LLC | 275.000 | 0 | 275.000 | 19.786.250 | Neu | +100,0% | |
| GILDER GAGNON HOWE & CO LLC | 271.758 | 208.302 | 63.456 | 19.552.988 | Aufgestockt | +30,5% | |
| Nearwater Capital Markets, Ltd | 261.500 | 61.500 | 200.000 | 18.814.925 | Aufgestockt | +325,2% | |
| EMERALD MUTUAL FUND ADVISERS TRUST | 256.106 | 253.125 | 2.981 | 18.426.827 | Aufgestockt | +1,2% | |
| Caption Management, LLC | 255.000 | 160.000 | 95.000 | 18.347.250 | Aufgestockt | +59,4% | |
| STATE STREET CORP | 244.727 | 195.656 | 49.071 | 17.608.108 | Aufgestockt | +25,1% | |
| BRAIDWELL LP | 222.701 | 0 | 222.701 | 16.023.337 | Neu | +100,0% | |
| Patient Square Capital LP | 210.000 | 0 | 210.000 | 15.109.500 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 204.952 | 224.837 | -19.885 | 14.746.296 | Reduziert | -8,8% | |
| TWO SIGMA ADVISERS, LP | 308.414 | 0 | 308.414 | 13.039.744 | Neu | +100,0% | |
| Quinn Opportunity Partners LLC | 179.247 | 85.868 | 93.379 | 12.896.822 | Aufgestockt | +108,7% | |
| Creek Drive Management Group LLC | 176.400 | 185.500 | -9.100 | 12.691.980 | Reduziert | -4,9% | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 295.716 | 0 | 295.716 | 12.502.872 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 168.007 | 120.380 | 47.627 | 12.088.104 | Aufgestockt | +39,6% | |
| DAFNA Capital Management LLC | 165.178 | 74.998 | 90.180 | 11.884.557 | Aufgestockt | +120,2% | |
| ADAR1 Capital Management, LLC | 161.252 | 72.031 | 89.221 | 11.602.081 | Aufgestockt | +123,9% | |
| MARSHALL WACE, LLP | 140.588 | 24.023 | 116.565 | 10.115.307 | Aufgestockt | +485,2% | |
| AMERIPRISE FINANCIAL INC | 136.730 | 0 | 136.730 | 9.837.702 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 126.942 | 147.793 | -20.851 | 9.133.477 | Reduziert | -14,1% | |
| SEVEN GRAND MANAGERS, LLC | 125.000 | 0 | 125.000 | 8.993.750 | Neu | +100,0% | |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | 122.326 | 188.112 | -65.786 | 8.801.356 | Reduziert | -35,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 121.539 | 210.298 | -88.759 | 8.744.731 | Reduziert | -42,2% | |
| Squarepoint Ops LLC | 107.385 | 20.257 | 87.128 | 7.726.351 | Aufgestockt | +430,1% | |
| Russell Investments Group, Ltd. | 106.248 | 85.666 | 20.582 | 7.644.546 | Aufgestockt | +24,0% | |
| STEMPOINT CAPITAL LP | 178.274 | 0 | 178.274 | 7.537.425 | Neu | +100,0% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| FMR LLC | 4.303.188 | 101.129 | +4155,1% | 309.614.403 | 15,83 |
| BVF INC/IL | 2.559.595 | 1.559.595 | +64,1% | 184.162.860 | 9,42 |
| Two Seas Capital LP | 1.959.178 | 745.185 | +162,9% | 140.962.857 | 7,21 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.197.055 | 0 | +100,0% | 86.128.107 | 4,40 |
| TWO SIGMA INVESTMENTS, LP | 930.741 | 473.014 | +96,8% | 66.966.815 | 3,42 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 903.190 | 1.158.310 | -22,0% | 64.984.521 | 3,32 |
| Prosight Management, LP | 735.000 | 554.633 | +32,5% | 52.883.250 | 2,70 |
| BlackRock, Inc. | 692.650 | 645.607 | +7,3% | 49.836.168 | 2,55 |
| CITADEL ADVISORS LLC | 665.431 | 489.377 | +36,0% | 47.877.760 | 2,45 |
| MORGAN STANLEY | 659.387 | 566.421 | +16,4% | 47.442.895 | 2,43 |
| ARMISTICE CAPITAL, LLC | 578.000 | 596.000 | -3,0% | 41.587.100 | 2,13 |
| Invesco Ltd. | 567.458 | 468.159 | +21,2% | 40.828.603 | 2,09 |
| Sofinnova Investments, Inc. | 509.546 | 438.630 | +16,2% | 36.661.835 | 1,87 |
| Woodline Partners LP | 415.335 | 104.000 | +299,4% | 29.883.353 | 1,53 |
| MILLENNIUM MANAGEMENT LLC | 404.277 | 454.075 | -11,0% | 29.087.730 | 1,49 |
| Bronte Capital Management Pty Ltd. | 400.756 | 0 | +100,0% | 28.834.394 | 1,47 |
| EMERALD ADVISERS, LLC | 394.604 | 384.342 | +2,7% | 28.391.758 | 1,45 |
| Qube Research & Technologies Ltd | 390.675 | 323.915 | +20,6% | 28.109.066 | 1,44 |
| GEODE CAPITAL MANAGEMENT, LLC | 346.795 | 254.361 | +36,3% | 24.961.900 | 1,28 |
| UBS Group AG | 320.172 | 287.561 | +11,3% | 23.036.375 | 1,18 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 213 | 29,8 | 2.096 |
| 31.12.2025 | ✓ | 179 | 19,8 | 819 |
| 30.09.2025 | ✓ | 156 | 19,0 | 1.043 |
| 30.06.2025 | ✓ | 113 | 10,6 | 249 |
| 31.03.2025 | ✓ | 155 | 131,7 | 84 |
| 31.12.2024 | ✓ | 142 | 135,2 | 118 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| Two Seas Capital LP | 745.185 | 31.506.422 |
| Prosight Management, LP | 554.633 | 23.449.883 |
| Creek Drive Management Group LLC | 185.500 | 7.842.940 |
| ING GROEP NV | 100.000 | 4.228.000 |
| Monashee Investment Management LLC | 94.134 | 3.979.986 |
| Ikarian Capital, LLC | 72.600 | 3.069.528 |
| Tetragon Partners GP Ltd | 69.287 | 2.929.454 |
| Voleon Capital Management LP | 68.335 | 2.889.204 |
| Nearwater Capital Markets, Ltd | 61.500 | 2.600.220 |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 60.431 | 2.555.023 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 596.000 | 328.000 | +122.4 % | 25.198.880 |
| Sofinnova Investments, Inc. | 438.630 | 320.211 | +270.4 % | 18.545.276 |
| Qube Research & Technologies Ltd | 323.915 | 319.941 | +8050.9 % | 13.695.126 |
| BVF INC/IL | 1.559.595 | 283.000 | +22.2 % | 65.939.677 |
| Point72 Asset Management, L.P. | 451.419 | 262.761 | +139.3 % | 19.085.995 |
| Invesco Ltd. | 468.159 | 241.262 | +106.3 % | 19.793.774 |
| BNP PARIBAS FINANCIAL MARKETS | 210.298 | 209.864 | +48355.8 % | 8.891.399 |
| UBS Group AG | 287.561 | 196.739 | +216.6 % | 12.158.079 |
| JANE STREET GROUP, LLC | 224.837 | 194.416 | +639.1 % | 9.506.109 |
| HRT FINANCIAL LP | 198.143 | 165.685 | +510.5 % | 8.377 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.158.310 | -625.786 | -35.1 % | 48.973.346 |
| MORGAN STANLEY | 566.421 | -362.730 | -39.0 % | 23.948.280 |
| CITADEL ADVISORS LLC | 489.377 | -359.700 | -42.4 % | 20.690.859 |
| Nantahala Capital Management, LLC | 112.946 | -305.576 | -73.0 % | 4.775.357 |
| Jefferies Financial Group Inc. | 111.900 | -191.300 | -63.1 % | 4.731.132 |
| SIMPLEX TRADING, LLC | 94.636 | -151.014 | -61.5 % | 4.001.210 |
| Woodline Partners LP | 104.000 | -129.059 | -55.4 % | 4.397.120 |
| MILLENNIUM MANAGEMENT LLC | 454.075 | -116.919 | -20.5 % | 19.198.291 |
| GROUP ONE TRADING LLC | 144.648 | -107.081 | -42.5 % | 6.115.717 |
| RENAISSANCE TECHNOLOGIES LLC | 172.881 | -105.660 | -37.9 % | 7.309.409 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 15.05.2026 | LAMPERT MARK N | Passiv (13G/A) | 9,80 % | 2.852.698 | +2,40 pp | |
| 15.05.2026 | BVF II GP LLC | Passiv (13G/A) | 3,90 % | 1.114.072 | +0,90 pp | |
| 15.05.2026 | BIOTECHNOLOGY VALUE FUND L P | Passiv (13G/A) | 5,30 % | 1.523.980 | +1,50 pp | |
| 15.05.2026 | BVF Partners OS Ltd. | Passiv (13G/A) | 0,60 % | 171.769 | +0,20 pp | |
| 15.05.2026 | BVF I GP LLC | Passiv (13G/A) | 5,30 % | 1.523.980 | +1,50 pp | |
| 15.05.2026 | BVF GP HOLDINGS LLC | Passiv (13G/A) | 9,10 % | 2.638.052 | +2,30 pp | |
| 15.05.2026 | Biotechnology Value Trading Fund OS LP | Passiv (13G/A) | 0,60 % | 171.769 | +0,20 pp | |
| 15.05.2026 | BIOTECHNOLOGY VALUE FUND II LP | Passiv (13G/A) | 3,90 % | 1.114.072 | +0,90 pp | |
| 15.05.2026 | BVF PARTNERS L P/IL | Passiv (13G/A) | 9,80 % | 2.852.698 | +2,40 pp | |
| 15.05.2026 | BVF INC/IL | Passiv (13G/A) | 9,80 % | 2.852.698 | +2,40 pp | |
| 06.05.2026 | Abigail P. Johnson | Passiv (13G/A) | 15,00 % | 4.303.188 | +3,90 pp | |
| 06.05.2026 | FMR LLC | Passiv (13G/A) | 15,00 % | 4.303.188 | +3,90 pp | |
| 17.04.2026 | Two Seas Capital GP LLC | Passiv (13G) | 6,80 % | 1.959.178 | Neu | |
| 17.04.2026 | Sina Toussi | Passiv (13G) | 6,80 % | 1.959.178 | Neu | |
| 17.04.2026 | Two Seas Capital LP | Passiv (13G) | 6,80 % | 1.959.178 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -5,04 pp | |
| 06.03.2026 | Abigail P. Johnson | Passiv (13G) | 11,10 % | 3.036.761 | Neu | |
| 06.03.2026 | FMR LLC | Passiv (13G) | 11,10 % | 3.036.761 | Neu | |
| 13.02.2026 | G1 Execution Services, LLC | Passiv (13G/A) | 4,00 % | 809.967 | Neu | |
| 13.02.2026 | Susquehanna Portfolio Strategies, LLC | Passiv (13G/A) | 4,00 % | 809.967 | -2,30 pp | |
| 13.02.2026 | Susquehanna Securities, LLC | Passiv (13G/A) | 4,00 % | 809.967 | -2,30 pp | |
| 30.01.2026 | The Vanguard Group | Passiv (13G) | 5,04 % | 1.027.089 | +0,06 pp | |
| 14.11.2025 | TCG Crossover GP II, LLC | Passiv (13G/A) | Ausstieg | 0 | -9,30 pp | |
| 14.11.2025 | TCG Crossover Fund II, L.P. | Passiv (13G/A) | Ausstieg | 0 | -9,30 pp | |
| 14.11.2025 | Chen Yu | Passiv (13G/A) | Ausstieg | 0 | -9,30 pp | |
| 14.11.2025 | Wilmot B. Harkey | Passiv (13G/A) | 2,20 % | 418.522 | -3,52 pp | |
| 14.11.2025 | Daniel Mack | Passiv (13G/A) | 2,20 % | 418.522 | -3,52 pp | |
| 14.11.2025 | Nantahala Capital Management, LLC | Passiv (13G/A) | 2,20 % | 418.522 | -3,52 pp | |
| 13.11.2025 | Susquehanna Portfolio Strategies, LLC | Passiv (13G) | 6,30 % | 1.235.864 | Neu | |
| 13.11.2025 | Susquehanna Securities, LLC | Passiv (13G) | 6,30 % | 1.235.864 | Neu | |
| 31.10.2025 | The Vanguard Group | Passiv (13G/A) | 4,98 % | 948.647 | -1,33 pp | |
| 28.10.2025 | Millennium Group Management LLC | Passiv (13G/A) | 3,00 % | 570.994 | -2,40 pp | |
| 28.10.2025 | Millennium Management LLC | Passiv (13G/A) | 3,00 % | 570.994 | -2,40 pp | |
| 28.10.2025 | Integrated Core Strategies (US) LLC | Passiv (13G/A) | 1,80 % | 333.576 | -2,90 pp | |
| 28.10.2025 | Israel A. Englander | Passiv (13G/A) | 3,00 % | 570.994 | -2,40 pp | |
| 14.08.2025 | Daniel Mack | Passiv (13G) | 5,72 % | 709.761 | Neu | |
| 14.08.2025 | Nantahala Capital Management, LLC | Passiv (13G) | 5,72 % | 709.761 | Neu | |
| 14.08.2025 | Wilmot B. Harkey | Passiv (13G) | 5,72 % | 709.761 | Neu | |
| 14.08.2025 | TCG Crossover Fund II, L.P. | Passiv (13G/A) | 9,30 % | 1.933.333 | Neu | |
| 14.08.2025 | Chen Yu | Passiv (13G/A) | 9,30 % | 1.933.333 | Neu |
Stammdaten
Nektar Therapeutics, ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entdeckung und Entwicklung von Arzneimitteln in Bereichen mit ungedecktem medizinischem Bedarf in den Vereinigten Staaten und international. Die Produkte des Unternehmens umfassen Bempegaldesleukin, einen CD122-bevorzugten Interleukin-2 (IL-2) Signalweg-Agonisten, der sich in einer Phase-3-Klinischen Studie zur Behandlung von metastasierten Melanom, Nierenzellkarzinom, muskelinvasiven Blasenkrebs, Plattenepithelkarzinom des Kopf- und Halsbereichs und adjuvantem Melanom befindet; Phase-2-Klinische Studie zur Behandlung von Nierenzellkarzinom, nicht-kleinzelligem Lungenkrebs und Urothelkarzinom; Phase-1/2A-Klinische Studie zur Behandlung von Plattenepithelkarzinom des Kopf- und Halsbereichs; Phase-1/2-Klinische Studie zur Behandlung von soliden Tumoren; und Phase-1B-Klinische Studie zur Behandlung von COVID-19. Das Unternehmen entwickelt auch NKTR-358, einen Zytokin-Treg-Stimulator, der sich in einer Phase-2-Klinischen Studie zur Behandlung von systemischem Lupus erythematodes und Colitis ulcerosa befindet, sowie einer Phase-1B-Klinischen Studie zur Behandlung von atopischer Dermatitis und Psoriasis; NKTR-255, einen IL-15-Rezeptor-Agonisten, der sich in einer Phase-1/2-Klinischen Studie zur Behandlung von Non-Hodgkin-Lymphom und Multiplem Myelom sowie Kopf- und Halskrebs und Kolorektalkarzinom befindet; und NKTR-262, einen Toll-ähnlichen Rezeptor-Agonisten, der sich in einer Phase-1/2-Klinischen Studie zur Behandlung von soliden Tumoren befindet, sowie verschiedene andere Arzneimittelkandidaten. Das Unternehmen verfügt über Kooperationsvereinbarungen mit Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; und SFJ Pharmaceuticals, Inc. Nektar Therapeutics wurde 1990 gegründet und hat seinen Hauptsitz in San Francisco, Kalifornien.
Unternehmen & Branche
| Name | NEKTAR THERAPEUTICS |
|---|---|
| Ticker | NKTR |
| CIK | 0000906709 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 640268108 |
|---|---|
| ISIN | US6402681083 |
| Typ | Common Stock |
| Marktkapitalisierung | 1,16 Mrd. USD |
| Beta | 1,23 |
Bewertung
| KBV (P/B) | 12,88 vs. 55,31 (2021) ▼ |
|---|---|
| KUV (P/S) | 20,95 vs. 368,82 (2021) ▼ |
| FCF-Rendite | -18,0 % vs. -1,1 % (2021) ▼ |
| Buyback-Rendite | 0,0 % |
Qualität & Bilanz
| Bruttomarge | 100,0 % vs. 75,6 % (2021) ▲ |
|---|---|
| Operative Marge | -253,7 % vs. -437,8 % (2021) ▲ |
| Nettomarge | -297,1 % vs. -514,0 % (2021) ▲ |
| ROIC | -93,4 % vs. -63,7 % (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 55,31 | 17,43 | 12,39 | 2,84 | 9,59 | |
| KUV (P/S) | 368,82 | 69,44 | 18,01 | 1,76 | 15,60 | |
| FCF-Rendite | -1,1 % | -4,8 % | -11,9 % | -102,6 % | -24,2 % | |
| Buyback-Rendite | – | – | 0,0 % | 1,7 % | 0,0 % | |
| Qualität & Bilanz | ||||||
| Bruttomarge | 75,6 % | 76,5 % | 62,5 % | 68,8 % | 100,0 % | |
| Operative Marge | -437,8 % | -408,6 % | -292,6 % | -106,9 % | -253,7 % | |
| Nettomarge | -514,0 % | -400,0 % | -306,3 % | -120,9 % | -297,1 % | |
| ROIC | -63,7 % | -73,9 % | -111,0 % | -72,8 % | -93,4 % | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 10.861.000 | -44.904.000 | -1,82 | 763.271.000 | 576.216.000 |
| 2025-12-31 | 10-K | 55.232.000 | -164.076.000 | -9,73 | 280.406.000 | 89.832.000 |
| 2025-09-30 | 10-Q | 11.790.000 | -35.522.000 | -1,87 | 301.347.000 | 85.086.000 |
| 2025-06-30 | 10-Q | 11.175.000 | -41.593.000 | -2,95 | 207.534.000 | -24.211.000 |
| 2025-03-31 | 10-Q | 10.460.000 | -50.882.000 | -0,24 | 256.241.000 | 13.738.000 |
| 2024-12-31 | 10-K | 98.427.000 | -118.961.000 | -0,58 | 303.850.000 | 60.737.000 |
| 2024-09-30 | 10-Q | 24.124.000 | -37.057.000 | -0,18 | 307.966.000 | 48.884.000 |
| 2024-06-30 | 10-Q | 23.489.000 | -52.363.000 | -0,25 | 343.334.000 | 79.688.000 |
| 2024-03-31 | 10-Q | 21.639.000 | -36.802.000 | -0,19 | 396.012.000 | 126.705.000 |
| 2023-12-31 | 10-K | 90.122.000 | -276.056.000 | -1,45 | 398.033.000 | 130.987.000 |
| 2023-09-30 | 10-Q | 24.144.000 | -45.837.000 | -0,24 | 442.244.000 | 159.368.000 |
| 2023-06-30 | 10-Q | 20.499.000 | -51.122.000 | -0,27 | 494.279.000 | 196.958.000 |
| 2023-03-31 | 10-Q | 21.594.000 | -137.018.000 | -0,73 | 561.743.000 | 240.865.000 |
| 2022-12-31 | 10-K | 92.055.000 | -368.198.000 | -1,97 | 710.600.000 | 366.638.000 |
| 2022-09-30 | 10-Q | 23.625.000 | -59.049.000 | -0,31 | 781.006.000 | 412.223.000 |
| 2022-06-30 | 10-Q | 21.585.000 | -159.068.000 | -0,85 | 861.987.000 | 458.732.000 |
| 2022-03-31 | 10-Q | 24.822.000 | -90.393.000 | -0,49 | 1.024.116.000 | 607.889.000 |
| 2021-12-31 | 10-K | 101.907.000 | -523.837.000 | -2,86 | 1.117.189.000 | 679.508.000 |
| 2021-09-30 | 10-Q | 24.921.000 | -129.706.000 | -0,70 | 1.277.243.000 | 801.540.000 |
| 2021-06-30 | 10-Q | 28.330.000 | -125.519.000 | -0,69 | 1.371.351.000 | 904.975.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Non Cash Royalty Revenue Related To Sale Of Future Royalties | 54,9 Mio. | 64,3 Mio. | 68,9 Mio. | 69,8 Mio. | 77,7 Mio. | 49,9 % | -14,5% | |
| Non Cash Royalties | 54,9 Mio. | 64,3 Mio. | 68,9 Mio. | – | – | 49,8 % | -14,6% | |
| License Collaboration And Other Revenue | 300.000 | 597.000 | 520.000 | 1,9 Mio. | 436.000 | 0,3 % | -49,7% | |
| Product | – | 33,6 Mio. | 20,7 Mio. | 20,3 Mio. | 23,7 Mio. | – | – | |
| Cash And Non Cash Royalties | – | – | – | 69,8 Mio. | 77,7 Mio. | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 08.05.2026 | 10,9 Mio. USD | -1,82 |
| Q3 2025 | 30.09.2025 | 07.11.2025 | 11,8 Mio. USD | -1,87 |
| Q2 2025 | 30.06.2025 | 08.08.2025 | 11,2 Mio. USD | -2,95 |
| Q1 2025 | 31.03.2025 | 08.05.2026 | 10,5 Mio. USD | -3,62 |
| Q3 2024 | 30.09.2024 | 07.11.2025 | 24,1 Mio. USD | -2,66 |
| Q2 2024 | 30.06.2024 | 08.08.2025 | 23,5 Mio. USD | -3,76 |
| Q1 2024 | 31.03.2024 | 09.05.2025 | 21,6 Mio. USD | -0,19 |
| Q3 2023 | 30.09.2023 | 08.11.2024 | 24,1 Mio. USD | -0,24 |
| Q2 2023 | 30.06.2023 | 09.08.2024 | 20,5 Mio. USD | -0,27 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 08.05.2026 | 10-Q | 31.03.2026 | 38 Tage | SEC » |
| 13.03.2026 | 10-K | 31.12.2025 | 72 Tage | SEC » |
| 07.11.2025 | 10-Q | 30.09.2025 | 38 Tage | SEC » |
| 08.08.2025 | 10-Q | 30.06.2025 | 39 Tage | SEC » |
| 09.05.2025 | 10-Q | 31.03.2025 | 39 Tage | SEC » |
| 14.03.2025 | 10-K | 31.12.2024 | 73 Tage | SEC » |
| 08.11.2024 | 10-Q | 30.09.2024 | 39 Tage | SEC » |
| 09.08.2024 | 10-Q | 30.06.2024 | 40 Tage | SEC » |
| 10.05.2024 | 10-Q | 31.03.2024 | 40 Tage | SEC » |
| 05.03.2024 | 10-K | 31.12.2023 | 65 Tage | SEC » |
| 08.11.2023 | 10-Q | 30.09.2023 | 39 Tage | SEC » |
| 09.08.2023 | 10-Q | 30.06.2023 | 40 Tage | SEC » |
| 10.05.2023 | 10-Q | 31.03.2023 | 40 Tage | SEC » |
| 28.02.2023 | 10-K | 31.12.2022 | 59 Tage | SEC » |
| 04.11.2022 | 10-Q | 30.09.2022 | 35 Tage | SEC » |
| 05.08.2022 | 10-Q | 30.06.2022 | 36 Tage | SEC » |
| 06.05.2022 | 10-Q | 31.03.2022 | 36 Tage | SEC » |
| 01.03.2022 | 10-K | 31.12.2021 | 60 Tage | SEC » |
| 05.11.2021 | 10-Q | 30.09.2021 | 36 Tage | SEC » |
| 06.08.2021 | 10-Q | 30.06.2021 | 37 Tage | SEC » |
| 07.05.2021 | 10-Q | 31.03.2021 | 37 Tage | SEC » |
| 26.02.2021 | 10-K | 31.12.2020 | 57 Tage | SEC » |
| 06.11.2020 | 10-Q | 30.09.2020 | 37 Tage | SEC » |
| 07.08.2020 | 10-Q | 30.06.2020 | 38 Tage | SEC » |
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 21.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 17.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | severance and termination payments. Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 11.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 01.07.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 25.04.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 15.11.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |